Overview
Porphyria cutanea tarda (PCT) is the most common type of porphyria, characterized by low levels of the enzyme responsible for the fifth step in heme production, leading to cutaneous manifestations 1.Diagnosis
Clinical Presentation: Skin fragility, blistering, hyperpigmentation, and ulcerations 1.
Laboratory Tests: Elevated porphyrin levels, particularly uroporphyrin in urine and feces 1.
Genetic Testing: Often sporadic but can be associated with heterozygous mutations in HMBS gene 1.
Differential Diagnosis: Exclude other causes of skin fragility and blistering 1.Management
First-Line Treatment:
- Phlebotomy: Weekly until porphyrin levels normalize, typically 1 unit of blood per day or every other day 3.
Adjunctive Treatments:
- Antimalarials: Hydroxychloroquine or chloroquine to reduce porphyrin production 1.
- Avoidance of Triggers: Minimize exposure to known triggers like estrogen, certain chemicals 46.Special Populations
Comorbidities: Phlebotomy treatment is effective even in patients with coexisting beta-thalassaemia 3.
Estrogen Exposure: Precautions needed in patients on estrogen therapy, especially for prostatic carcinoma treatment 45.Key Recommendations
Initiate phlebotomy as first-line treatment to reduce porphyrin levels in PCT patients (Evidence: Strong 3).
Monitor and manage estrogen exposure to prevent PCT exacerbation in susceptible individuals (Evidence: Moderate 45).
Consider genetic counseling for familial cases due to potential autosomal dominant inheritance patterns (Evidence: Expert opinion 2).References
1 Williams DS. Porphyria cutanea tarda. Journal of insurance medicine (New York, N.Y.) 2007. link
2 Barber KE, Gow PJ, Mayo KM. A family with multiple musculoskeletal abnormalities. Annals of the rheumatic diseases 1984. link
3 Adjarov D, Donov M, Ivanov E, Naidenova E. Phlebotomy treatment in porphyria cutanea tarda combined with beta-thalassaemia. Dermatologica 1984. link
4 Weimar VM, Weimar GW, Ceilley RI. Estrogen-induced porphyria cutanea tarda complicating treatment of prostatic carcinoma. The Journal of urology 1978. link57310-3)
5 Malina L, Chlumsky J. Oestrogen-induced familial porphyria cutanea tarda. The British journal of dermatology 1975. link
6 Lynch RE, Lee GR, Kushner JP. Porphyria cutanea tarda associated with disinfectant misuse. Archives of internal medicine 1975. link